Gene and immunotherapy of liver diseases;Gen- und immuntherapie von lebererkrankungen

Internist

Volumn 42, Issue 10, 2001, Pages 1357-1365

  Cantz, T ^a   Ott, M ^a   Kubicka, S ^a   Manns, M P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BLOOD CLOTTING FACTOR 8; DNA VACCINE; PROTEIN P53; VIRUS VECTOR;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CANCER INHIBITION; CRIGLER NAJJAR SYNDROME; CYSTIC FIBROSIS; DUBIN JOHNSON SYNDROME; FAMILIAL HYPERCHOLESTEROLEMIA; GAUCHER DISEASE; GENE THERAPY; GENE TRANSFER; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS B; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INTRAHEPATIC CHOLESTASIS; LIVER CANCER; LIVER DISEASE; ONCOGENE N RAS; PHENYLKETONURIA; REVIEW; SUICIDE GENE; TREATMENT INDICATION; WILSON DISEASE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; GENE THERAPY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; IMMUNOTHERAPY; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS;

EID: 0034796613     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080170057     Document Type: Review

References (59)

1. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia
2. Gene therapy - A loss of innocence
3. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo
4. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses
5. 1-antitrypsin with negligible toxicity
6. Long term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII deficient mice
7. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver
8. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
9. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus
10. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors
11. Therapeutic levels of human factor VIII and IX using HIV-1 -based lentiviral vectors in mouse liver
12. Efficient gene transfer into various mammalian cells, including non-hepatic cells, by baculovirus vectors
13. Gene expression following direct injection of DNA into liver
14. Expression of naked plasmid DNA injected into the afferent and eferent vessels of rodent and dog livers
15. Somatic integration and long-term expression in normal and haemophilic mice using a DNA transposon system
16. Ex vivo hepatic gene therapy of a mouse model of hereditary Tyrosinemia Type I
17. Therapeutic liver repopulation in a mouse model of hypercholesterolemia
18. Correction of the UDP-glucuronosyltransferase gene defect in the gunn rat model of crigler-najjar syndrome type I with a chimeric oligonucleotide
19. Cellular and humoral immune response to hepatitis B virus structural proteins in mice after DNA-based immunization
20. DNA-mediated immunization to hepatitis B surface antigen: Longevity of primary response and effect of boost
21. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes
22. DNA vaccine for hepatitis B: Evidence for immunogenicity in chimpanzees and comparison with other vaccines
23. DNA-mediated immunization in a transgenic mouse model of the hepatitis B virus surface antigen chronic carrier state
24. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice
25. Gene therapy for chronic viral hepatitis: Ribozymes, antisense oligonucleotides and dominant negative mutants
26. Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection
27. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides
28. Recent advances in the molecular biology of hepatitis B virus
29. Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells
30. In vivo inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides in athymic nude mice
31. In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides
32. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides
33. Targeted delivery of antisense DNA in woodchuck hepatitis virus-infected woodchucks
34. Immune responses to plasmid DNA encoding the hepatitis C virus core protein
35. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids
36. Plasmid DNA-based immunization for hepatitis C virus structural proteins: Immune responses in mice
37. Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode
38. Modulation of immune responses to hepatitis C virus envelope E2 protein following injection of plasmid DNA using single or combined delivery routes
39. Core specific antisense phosphor-othioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation
40. Targeted inhibition of hepatitis C virus-directed gene expression in human hepatoma cell lines
41. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes
42. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes
43. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery
44. Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by ret roviral-mediated transfer of the wild-type p53 gene
45. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce tumor cell death
46. Expression of N-ras gene in human primary hepatocarcinoma
47. Construction and packaging of pseudotype retrovirus containing human N-ras cDNA antisense sequence and its biological effects on human hepatoma cells
48. Inhibition of fibroblast growth factor 2 expression by antisense RNA induced a loss of the transformed phenotype in a human hepatoma cell line
49. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene
50. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: Regression of hepatic metastasis of pancreatic tumors
51. A "distant" bystander effect of suicide gene therapy: Regression of nontransduced tumors together with a distant transduced tumor
52. Gene therapy for hepatocellular carcinoma: Long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo
53. Large nontransplanted hepatocellular carcinoma in woodchucks: Treatment with adenovirusmediated delivery of interleukin 12/B7.1 genes
54. Molecular mechanisms of developmental and tumor angiogenesis
55. Intratumor microvessel density as a prognostic factor in cancer
56. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2
57. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
58. The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factor
59. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue